



February 3, 2014

## **ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 10, 2014**

LOS ANGELES, Feb. 3, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 16<sup>th</sup> Annual BIO CEO & Investor Conference at 1:30 pm ET on Monday, February 10, 2014, at the Waldorf Astoria Hotel in New York City.

(Logo: <http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO>)

To access the live audio webcast of the BioCentury NewsMakers presentation, please log on through a link located in the Investors section of ImmunoCellular's website at [www.imuc.com](http://www.imuc.com), under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.

### About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit [www.imuc.com](http://www.imuc.com).

### Contact:

For ImmunoCellular Therapeutics, Ltd.  
Jane Green.  
Investor Relations  
415.348.0010  
[jane@jmgcomm.com](mailto:jane@jmgcomm.com)

SOURCE ImmunoCellular Therapeutics, Ltd.

News Provided by Acquire Media